ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

upadacitinib

Also written as “Upadacitinib”, “ABT-494” and “Upadacitinib 15 MG [Rinvoq]”.

Its studies are mostly in Dermatitis, Atopic · Arthritis, Rheumatoid · Crohn Disease · Colitis, Ulcerative · Alopecia Areata, led by 3 companies.

Drug pageUpadacitinib: every studyAll 98 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Aug 18, 202264 company-led studies, 24 open or runningNext primary completion: Nov 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie6121 open or runningphase 4since Aug 18, 2022Dec 3, 2012Nov 2026phase 3 · NCT06389136
CARE ARTHRITISits history only22 open or runningphase 4since Jun 6, 2024Jun 6, 2024May 2027phase 4 · NCT07018206
Modern Biosciencesits history only11 open or runningphase 1since Apr 8, 2024Apr 8, 2024none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AbbVie only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 47 earlier studies, Oct 9, 2013 to Aug 22, 2023.

  1. Jun 9, 2016Named upadacitinibINNProposed as its International Nonproprietary Name in WHO's List 115 · before, ABT-494
  2. Nov 1, 2023Phase 3 study in VitiligoNCT06118411 · 614 enrolled · United States, Argentina, Belgium and more
  3. Mar 19, 2024Phase 3 study in Crohn DiseaseNCT06332534 · 111 enrolled · United States, Australia, Belgium and more
  4. Apr 25, 20242 phase 3 studies in Dermatitis, AtopicNCT06389136, NCT06390722
  5. Jun 12, 2024Phase 3 study in Dermatitis, AtopicNCT06461897 · 699 enrolled · United States, Argentina, Australia and more
  6. Nov 21, 2024Phase 3 study in Dermatitis, AtopicNCT06701331 · 99 enrolled · Japan
  7. Jun 10, 2025Phase 3 study in Alopecia AreataNCT07023302 · 125 enrolled · Japan
  8. Feb 17, 2026Phase 1 study in Healthy VolunteerNCT07425899 · 16 enrolled · United States
  9. Aug 11, 2026Phase 3 study in Alopecia AreataNCT07772492 · 300 planned · United States, Australia, Japan and more
  10. Sep 22, 2026Phase 1 study in Healthy VolunteersNCT07843693 · 60 planned · United States
  11. Oct 16, 2026Primary completion moved from 2027-06 to 2031-01Date moved laterphase 3 · +43 months · NCT06332534
  12. Oct 16, 2026Primary completion moved from 2026-08 to 2026-11Date moved laterphase 3 · +3 months · NCT06389136
  13. Oct 21, 20262 phase 3 studiesNCT07896434, NCT07933211
  14. Oct 23, 2026Phase 2 study in Arthritis, RheumatoidNCT07904754 · 250 planned
  15. Nov 13, 2026Primary completion moved from 2028-03 to 2028-08Date moved laterphase 3 · +5 months · NCT05889182

Ahead

  1. Nov 2026Primary completion: phase 3 study in Dermatitis, AtopicNCT06389136
  2. Dec 2026Primary completion: phase 1 study in Healthy VolunteersNCT07843693
  3. Jan 2027Primary completion: phase 3 study in Dermatitis, AtopicNCT06701331
  4. Mar 2027Primary completion: phase 3 study in Lupus Erythematosus, SystemicNCT05843643

TargetBeta

“Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK1 inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
ruxolitinibruleIncytephase 495
tofacitinibrulePfizerphase 494
filgotinib maleateruleEisaiphase 42
filgotinibruleLakefront Biotherapeutics NVphase 346
delgocitinibruleLEO Pharmaphase 321

Studies

The newest 60 of 61 AbbVie leads. Each opens its study page. Every study on its drug page →

StudyPhaseStatusPrimary completionSize
NCT07933211Scleroderma, Systemic3Not yet recruitingJun 2035580
NCT07904754Arthritis, Rheumatoid2Not yet recruitingJul 2029250
NCT07896434Non-Segmental Vitiligo3Not yet recruitingAug 2032154
NCT07843693Healthy Volunteers · United States1RecruitingDec 202660
NCT07772492Alopecia Areata · United States, Australia, Japan and more3RecruitingMar 2032300
NCT07425899Healthy Volunteer · United States1CompletedJun 5, 202616
NCT07023302Alopecia Areata · Japan3Active, not recruitingFeb 2029125
NCT06701331Dermatitis, Atopic · Japan3Active, not recruitingJan 202799
NCT06461897Dermatitis, Atopic · United States, Argentina, Australia and more3Active, not recruitingNov 2029699
NCT06390722Dermatitis, Atopic3WithdrawnJan 5, 20260
NCT06389136Dermatitis, Atopic · United States, Canada, Colombia and more3Active, not recruitingNov 2026184
NCT06332534Crohn Disease · United States, Australia, Belgium and more3Active, not recruitingJan 2031111
NCT06118411Vitiligo · United States, Argentina, Belgium and more3Active, not recruitingMar 2028614
NCT06012240Alopecia Areata · United States, Argentina, Australia and more3RecruitingApr 20301,500
NCT05889182Hidradenitis Suppurativa · United States, Argentina, Australia and more3Active, not recruitingAug 20281,328
NCT05843643Lupus Erythematosus, Systemic · United States, Argentina, Australia and more3Active, not recruitingMar 20271,014
NCT05814627Arthritis, Rheumatoid · United States, Argentina, Belgium and more3CompletedJul 15, 2026487
NCT05782907Colitis, Ulcerative · United States, Australia, Belgium and more3Active, not recruitingAug 2028122
NCT05609630Arthritis, Juvenile · United States, Argentina, Australia and more3RecruitingJun 202990
NCT05601882Dermatitis, Atopic · United States, Australia, Belgium and more3CompletedMar 19, 2024920
NCT05507580Dermatitis, Atopic · Australia, Belgium, Bulgaria and more4CompletedJul 11, 2024461
NCT04927975Vitiligo · United States, Canada, France and more2CompletedJan 13, 2023185
NCT04666675Dermatitis, Atopic3WithdrawnMar 23, 20210
NCT04451772Lupus Erythematosus, Systemic · United States, Argentina, Australia and more2CompletedJan 3, 2024185
NCT04430855Hidradenitis Suppurativa · United States, Canada, Japan and more2CompletedApr 22, 202168
NCT04195698Dermatitis, Atopic · United States, Australia, Canada and more3CompletedSep 11, 2023475
NCT04169373Spondylarthritis · United States, Argentina, Australia and more3CompletedSep 2, 2021734
NCT04161898Takayasu Arteritis · Argentina, Brazil, China and more3Active, not recruitingAug 202856
NCT03978520Lupus Erythematosus, Systemic · United States, Argentina, Australia and more2CompletedJan 19, 2022341
NCT03823378Arthritis, Rheumatoid · Belgium, Canada, Czechia and more2TerminatedSep 9, 202097
NCT03738397Dermatitis, Atopic · United States, Australia, Canada and more3CompletedAug 27, 2020673
NCT03725202Giant Cell Arteritis · United States, Australia, Austria and more3CompletedFeb 6, 2024429
NCT03725007Arthritis, Juvenile · United States, Canada, Germany and more1Active, not recruitingDec 2028124
NCT03682705Arthritis, Rheumatoid · United States, Belgium, Canada and more2CompletedMar 26, 2020242
NCT03661138Dermatitis, Atopic · Japan3CompletedAug 19, 2022272
NCT03653026Colitis, Ulcerative · United States, Argentina, Australia and more3CompletedJan 14, 2021522
NCT03646604Dermatitis, Atopic · United States, Norway, Puerto Rico1CompletedAug 29, 202435
NCT03607422Dermatitis, Atopic · United States, Australia, Austria and more3CompletedMar 11, 2021912
NCT03569293Dermatitis, Atopic · United States, Argentina, Australia and more3CompletedJan 6, 2021912
NCT03568318Dermatitis, Atopic · United States, Australia, Austria and more3Active, not recruitingFeb 16, 20211,533
NCT03345849Crohn Disease · United States, Argentina, Australia and more3CompletedOct 15, 2021526
NCT03345836Crohn Disease · United States, Argentina, Australia and more3CompletedAug 11, 2021624
NCT03345823Crohn Disease · United States, Argentina, Australia and more3Active, not recruitingSep 2027747
NCT03178487Spondylitis, Ankylosing · United States, Australia, Belgium and more2CompletedJan 21, 2019187
NCT03104400Arthritis, Psoriatic · United States, Argentina, Australia and more3CompletedSep 26, 20191,705
NCT03104374Arthritis, Psoriatic · United States, Australia, Belgium and more3CompletedJul 23, 2019642
NCT03006068Colitis, Ulcerative · United States, Argentina, Australia and more3Active, not recruitingJul 2027950
NCT02955212Arthritis, Rheumatoid · Brazil, China, Korea, Republic of3CompletedAug 14, 2019338
NCT02925117Dermatitis, Atopic · United States, Australia, Canada and more2CompletedAug 10, 2017167
NCT02819635Colitis, Ulcerative · United States, Argentina, Australia and more3CompletedDec 13, 20211,302
NCT02782663Crohn Disease · United States, Belgium, Canada and more2CompletedJul 18, 2025107
NCT02720523Arthritis, Rheumatoid · Japan3CompletedAug 3, 2017197
NCT02706951Arthritis, Rheumatoid · United States, Argentina, Australia and more3CompletedOct 2, 2017648
NCT02706873Arthritis, Rheumatoid · United States, Argentina, Australia and more3CompletedMar 15, 20181,002
NCT02706847Arthritis, Rheumatoid · United States, Australia, Austria and more3CompletedApr 3, 2017499
NCT02675426Arthritis, Rheumatoid · United States, Argentina, Australia and more3CompletedApr 21, 2017661
NCT02365649Crohn Disease2CompletedNov 25, 2016220
NCT02066389Arthritis, Rheumatoid · United States, Bulgaria, Chile and more2CompletedJul 2, 2015300
NCT02049138Arthritis, Rheumatoid · United States, Belgium, Bulgaria and more2CompletedJul 29, 2021493
NCT01960855Arthritis, Rheumatoid2CompletedJul 2015276

How it is read

Names in the registry

  • “Upadacitinib”, 54 entries
  • “ABT-494”, 4 entries
  • “Upadacitinib 15 MG [Rinvoq]”, 2 entries
  • “Upadacitinib (ABT-494)”, 2 entries
  • “Upadacitinib 15mg Dose”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.